[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589740":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":22,"locations":30,"responsibleParty":64,"collaborators":67,"id":69,"slug":10,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":10,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":10,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":90,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Charite University, Berlin, Germany","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"patients with suspected neuroimmunological disease",null,"patients with suspected neuroimmunological disease in whom a lumbar puncture is indicated for routine clinical work-up and for treatment decisions",[13,17,20],{"name":14,"affiliation":15,"role":16},"Marc Nikolaus, MD","Charite - Universitaetsmedizin Berlin","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":19,"role":16},"Tumani Hayrettin, MD","University of Ulm",{"name":21,"affiliation":19,"role":16},"Maximilian Wiesenfarth, MD",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Markus Schuelke, MD","CONTACT","+49 30 450 566112","markus.schuelke@charite.de",{"name":14,"role":25,"phone":26,"phoneExt":10,"email":29},"marc.nikolaus@charite.de",[31,47],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Charité - Universitätsmedizin Berlin","RECRUITING","Berlin","State of Berlin","13353","Germany",{"type":39,"coordinates":40},"Point",[41,42],13.41053,52.52437,{"lat":42,"lon":41},[45,46],{"name":14,"role":25,"phone":26,"phoneExt":10,"email":29},{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},{"facility":48,"status":33,"city":49,"state":10,"zip":50,"country":37,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Universität Ulm","Ulm","89081",{"type":39,"coordinates":52},[53,54],9.99155,48.39841,{"lat":54,"lon":53},[57,61],{"name":58,"role":25,"phone":59,"phoneExt":10,"email":60},"Hayrettin Tumani, MD","+497311775206","hayrettin.tumani@uni-ulm.de",{"name":21,"role":25,"phone":62,"phoneExt":10,"email":63},"+497311775271","maximilian.wiesenfarth@rku.de",{"type":16,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Markus Schuelke, M.D.","Principal Investigator",[68],{"name":19,"class":6},"100589740",false,"NCT06958341","Neuroimmunology Registry and Biobank","Registry for Patients With Antibody-mediated Neuroimmunological Diseases","Inclusion Criteria:\n\n1. Differential diagnosis: suspected neuroimmunological disease in which a lumbar puncture is indicated for further diagnosis and treatment decision\n2. Individuals with unclear clinical diagnosis where additional CSF is to be collected for isolation of B cells and production of monoclonal antibodies. The clinical condition of the patients and his\u002Fher compliance have to allow an extra 2-3 ml of CSF to be collected.\n3. Age: all age groups\n4. Gender: patients of both sexes will be included\n\nExclusion criteria:\n\n\\[1\\] Withdrawal of consent","ALL",{"count":77,"type":78},300,"ESTIMATED","OBSERVATIONAL","A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specific or merely an epiphenomenon of inflammatory processes in the brain.\n\nThe registry was established with the following objectives: \\[1\\] Are antineuronal antibodies much more common than previously thought in various neurological disorders for which the etiology has not yet been elucidated? \\[2\\] Can further correlations, such as those between HSV infection and NMDA receptor autoimmunity, be identified? \\[3\\] Are these antibodies mainly non-specific epiphenomena or are they crucial for the pathogenesis? \\[4\\] What is the clinical course of patients with antineuronal antibodies and their response to therapy? These questions will be addressed in a broad immunohistological screening of a large number of CSF samples and a clinical database of patients with neurological disorders.",[82,83,84,85,86,87,88,89],"Encephalopathy","Psychosis","Impaired Consciousness","Epilepsy","Movement Disorders","Motor Neuropathy","Spasticity","Ataxia",[91,92,93,94],"neuroimmunological diseases","cerebrospinal fluid","cell-based assay","tissue-based assay","2025-05-03",{"date":97,"type":98},"2025-05-06","ACTUAL",{"date":100,"type":98},"2021-02-01",{"date":102,"type":78},"2031-07-01",{"name":5,"class":6},2]